|
Sofosbuvir/Ledipasvir in Treatment of Early (Acute) HCV Infection in HIV+ Men
|
|
|
Reported by Jules Levin
EASL 2017
![0622181](../images%20/062218/062218-4/0622181.gif)
7. Conclusions  
o All 22 (100%) HIV-infected men with early HCV were cured with short-course (8-week) SOF/LDV in h=this Real-World setting using broad enrollment and treatment criteria.  
o For future research, better definitions of early HCV infection are needed to determine eligibility for short-course treatment.  
o For clinical practice, early HCV infection should be treated as soon as possible after clinical onset to take advantage of short-course treatments, as well as to decrease transmission among HIV-infected MSM.
![0622182](../images%20/062218/062218-4/0622182.gif)
![0622183](../images%20/062218/062218-4/0622183.gif)
![0622184](../images%20/062218/062218-4/0622184.gif)
![0622185](../images%20/062218/062218-4/0622185.gif)
![0622186](../images%20/062218/062218-4/0622186.gif)
![0622187](../images%20/062218/062218-4/0622187.gif)
| |
|
|
|
|
|